Advertisement
Advertisement
CTXR
Citius Pharmaceuticals Inc. Common
0.72
USDSponsored
+0.02
+2.96%
Mar 25, 15:59 UTC -4
Closed
Pre-Market
0.75
+0.03
+3.89%
CTXR Earnings Reports
Positive Surprise Ratio
CTXR beat 9 of 27 last estimates.
33%
Next Report
Date of Next Report
May 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
$10.07M
/-$0.20
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q2 25 (Revenue/ EPS)
--
/-84.25%
Citius Pharmaceuticals Inc. Common earnings per share and revenue
On Feb 12, 2026, CTXR reported earnings of -- USD per share (EPS) for Q1 26, -- the estimate of -0.01 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 3.52 million, with a --% difference.
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.20 USD, with revenue projected to reach 10.07 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Talphera, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
Relmada Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.14
Actual
-$0.28
Surprise
-103.08%
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Journey Medical Corporation Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.04
Surprise
+31.86%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
FAQ
What were Citius Pharmaceuticals Inc. Common's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Citius Pharmaceuticals Inc. Common reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Citius Pharmaceuticals Inc. Common's Q1 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Citius Pharmaceuticals Inc. Common expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Citius Pharmaceuticals Inc. Common's next earnings report?
Based on 3
analysts, Citius Pharmaceuticals Inc. Common is expected to report EPS of -$0.20 and revenue of $10.07M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement